Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.

By Derek Lowe

Posts tagged with "Academia (vs. Industry)"

• Academia (vs. Industry)

  From Industry to Academia

  23 April, 2019

  Academic research and industrial drug discovery have always been on separate paths, but my impression is that the two understand each other better now than they have at any time during my career. That’s in no small part due to the number of industrial scientists who have moved into academia (itself in no small part… Read More

• Academia (vs. Industry)

  Startup Culture, Starting

  1 April, 2019

  Many readers of this blog work in the biopharma industry, naturally, and of those, many are in and around the (few) locations where a great many of the companies in the industry are born. I myself am in the Boston/Cambridge area, famously thick with companies large and small, and then you have the Bay area… Read More

• Academia (vs. Industry)

  Targets Versus Drugs

  5 February, 2019

  There was a comment on the blog the other day about how there are people in academia who feel that the discovery of a new target or pathway is basically finding a new drug, and that the rest is “technicalities”. I’ve encountered that view of the world before (Donald Light/Rebecca Warburton, Marcia Angell, and similarly Arnold… Read More

• Academia (vs. Industry)

  Rep. Ocasio-Cortez and Where Drugs Come From

  1 February, 2019

  There have been several hearings in Washington on the drug industry and drug prices, and there are going to be more. Drug pricing is a large and messy issue, for sure, and all I’ll say about it today is to ask everyone to read Jack Scannell on it before expressing an opinion. I’m not going… Read More

• Academia (vs. Industry)

  Industrial Manuscripts Not Welcome

  26 November, 2018

  Update: see the comments section. The editors of the journal are calling this “a highly unusual and unfortunate error” and are taking steps to correct it. Now, this is a situation that I haven’t seen mentioned before. A reader (from one division of a large pharma company that I won’t name) had prepared a manuscript… Read More

• Academia (vs. Industry)

  Reporting Clinical Trials

  20 September, 2018

  In 2015, a study looked at drug-industry sponsored clinical trials versus those funded by the NIH, and concluded that about 20% of industry trials did not report results when required to do so, while the figure for NIH-sponsored research was about 50% (and even more for trials funded by other institutions). At the time, I… Read More

• Academia (vs. Industry)

  Pressure For Academia?

  18 July, 2018

  I have enough time today for a quick question, one that’s also being asked by several people on Twitter. Back when I was a grad student, there was definite pressure on people to seek an academic position. I saw more than one group where this pressure was applied selectively to the more promising-seeming grad students/postdocs… Read More

• Academia (vs. Industry)

  Decline of the Midwest?

  19 October, 2017

  Here’s an article at The Atlantic (via the Washington Monthly) that should concern anyone involved in R&D. It’s about the funding problems of many of the large public universities, particularly in the Midwest. Chemists will recognize several historically strong departments in that part of the country – but may also have noted… Read More

• Academia (vs. Industry)

  Allow Me to Peruse Your Grant

  7 September, 2017

  This is one that I certainly hadn’t heard of until a few days ago. According to this article, academic scientists are using the Freedom of Information Act (FOIA) to get a look at other people’s grant applications. In the past few years, some scientists have complained that FOIA has been weaponized by activists and special interest gro… Read More

• Academia (vs. Industry)

  Changes in NIH Grant Policy?

  11 May, 2017

  There are some pretty big funding changes being proposed at the NIH that many people may not be aware of. A concerned NIH grantee has sent along some links and comments about these, and I think that they’re worth bringing up. Here’s a blog post by Mike Lauer of the NIH going into some details: Read More